ContractSupply and Packaging Services Agreement • March 30th, 2021 • Phathom Pharmaceuticals, Inc. • Pharmaceutical preparations • England and Wales
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. THE OMISSIONS HAVE BEEN INDICATED BY “[***].”
AMENDMENT NO. 1 TO LICENSE AGREEMENTLicense Agreement • March 30th, 2021 • Phathom Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment No. 1 (“Amendment”) is made effective as of September 21, 2020 (the “Amendment Effective Date”) by and between Phathom Pharmaceuticals, Inc., a company incorporated under the laws of Delaware having its principal place of business at 100 Campus Drive, Suite 102, Florham Park, NJ 07932 , U.S.A (“Licensee”), and Takeda Pharmaceutical Company Limited, a company incorporated under the laws of Japan having its principal place of business at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, Japan (“Takeda”) (Licensee and Takeda may be referred to herein individually as a “Party” and collectively as the “Parties”).
AMENDMENT 1 TO THE COMMERCIAL SUPPLY AGREEMENTCommercial Supply Agreement • March 30th, 2021 • Phathom Pharmaceuticals, Inc. • Pharmaceutical preparations
This amendment 1 (this “Amendment 1”) is made on December 1, 2020, to the commercial supply agreement effective on April 30, 2020 by and between Takeda Pharmaceutical Company Limited, a company incorporated under the laws of Japan having its principal place of business at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, Japan (“Takeda”) and Phathom Pharmaceuticals, Inc., a company incorporated under the laws of Delaware having its principal place of business at 2150 E. Lake Cook Road, Suite 800, Buffalo Grove, Illinois 60089, U.S.A. (“Company”). Takeda and Company are referred to herein individually as a “Party” and collectively as the “Parties.”
